Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza(®), Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoeconomics
Main Authors: Büyükkaramikli, Nasuh C., Blommestein, Hedwig M., Riemsma, Rob, Armstrong, Nigel, Clay, Fiona. J., Ross, Janine, Worthy, Gill, Severens, Johan, Kleijnen, Jos, Al, Maiwenn J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2017
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684255/
https://ncbi.nlm.nih.gov/pubmed/28656543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0528-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados